Dr. Zain Discusses Ongoing Trials in T-Cell Lymphomas

Jasmine Zain, MD
Published Online: Thursday, Dec 19, 2013
Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

At the Center for the Lymphoid Malignancies, researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas. The two agents approved in this space, vorinostat and romidepsin, both have response rates close to 30%. Zain says the goal is to improve on these response rates in the relapsed setting and even move them to the upfront setting.

Activity remains to be seen in a phase I trial looking at romidepsin and 5-azacytidine. In another trial, activity is just being observed with pralatrexate and romidepsin. Both trials are open and enrolling.

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

At the Center for the Lymphoid Malignancies, researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas. The two agents approved in this space, vorinostat and romidepsin, both have response rates close to 30%. Zain says the goal is to improve on these response rates in the relapsed setting and even move them to the upfront setting.

Activity remains to be seen in a phase I trial looking at romidepsin and 5-azacytidine. In another trial, activity is just being observed with pralatrexate and romidepsin. Both trials are open and enrolling.

Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: 11th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®May 29, 20161.5
32nd Annual Miami Breast Cancer Conference® Community Practice ConnectionsMay 29, 20161.25